References
- Anderson R, Haas M, Shanahan M (2008). The cost effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range? Aust New Zealand J Public Health, 32, 43-52. https://doi.org/10.1111/j.1753-6405.2008.00165.x
- Andres-Gamboa O, Chicaiza L, Garcia-Molina M, et al (2008). Cost-effectiveness of conventional cytology and HPV DNA testing for cervical cancer screening in Colombia. Salud Publica Mex, 50, 276-85. https://doi.org/10.1590/S0036-36342008000400005
- Arbyn M, Castellsague X, De Sanjose S, et al (2011). Worldwide burden of cervical cancer in 2008. Ann Oncol, 22, 2675-86. https://doi.org/10.1093/annonc/mdr015
- Bambha K, Kim WR (2004). Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. Eur J Gastroenterol Hepatol, 16, 519-26. https://doi.org/10.1097/00042737-200406000-00003
- Berkhof J, Coupe VM, Bogaards JA, et al (2010). The health and economic effects of HPV DNA screening in The Netherlands. Int J Cancer, 127, 2147-58. https://doi.org/10.1002/ijc.25211
- Bidus MA, Maxwell GL, Kulasingam S, et al (2006). Costeffectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening. Obstet Gynecol, 107, 997-1005. https://doi.org/10.1097/01.AOG.0000210529.70226.0a
- Bistoletti P, Sennfalt K, Dillner J (2008). Cost-effectiveness of primary cytology and HPV DNA cervical screening. Int J Cancer, 122, 372-76. https://doi.org/10.1002/ijc.23124
- Brown AD ,Garber AM (1999). Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA. 281, 347-53. https://doi.org/10.1001/jama.281.4.347
- Burger E, Ortendahl J, Sy S, et al (2012). Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br J Cancer, 106, 1571-8 https://doi.org/10.1038/bjc.2012.94
- Cantor SB, Fahs MC, Mandelblatt JS, Myers ER, Sanders GD (2003). Decision science and cervical cancer. Cancer, 98, 2003-8. https://doi.org/10.1002/cncr.11680
- Chen H, Shu H-M, Chang Z-L, et al (2012). Efficacy of Pap test in combination with ThinPrep cytological test in screening for cervical cancer. Asian Pac J Cancer Prev, 13, 1651-5. https://doi.org/10.7314/APJCP.2012.13.4.1651
- Chow IHI, Tang C, You S, et al (2010). Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. Br J Cancer, 103, 1773-82. https://doi.org/10.1038/sj.bjc.6605974
- Chuck A (2010). Cost-effectiveness of 21 alternative cervical cancer screening strategies. Value in Health, 13, 169-79. https://doi.org/10.1111/j.1524-4733.2009.00611.x
- Davey E, D' assuncao J, Irwig L, et al (2007). Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ, 335, 31. https://doi.org/10.1136/bmj.39219.645475.55
- De Kok IMCM, Van Rosmalen J, Dillner J, et al (2012). Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. Bri Med J, 344, 1-14.
- Denton K J, Bergeron C, Klement P, et al (2010). The sensitivity and specificity of p16INK4a cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASCUS and LSIL Pap cytology results. Am J Clin Pathol, 134, 12-21. https://doi.org/10.1309/AJCP3CD9YKYFJDQL
- Devlin N, Parkin D (2004). Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Economics, 13, 437-52. https://doi.org/10.1002/hec.864
- Dickinson JA, Stankiewicz A, Popadiuk C, et al (2012). Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health, 12, 992. https://doi.org/10.1186/1471-2458-12-992
- Drummond M ,Weatherly H (2000). Implementing the findings of health technology assessments. Int J Technol Assess Health Care, 16, 1-12. https://doi.org/10.1017/S0266462300016111
- Drummond Mf SM, Torrance G, O'Brien B, Stoddart G (2005). Methods for the economic evaluation of health care programmes. Oxford University Press, New York volume 3.
- Eichler H-G, Kong SX, Gerth WC, et al (2004). Use of costeffectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value iHealth, 7, 518-28. https://doi.org/10.1111/j.1524-4733.2004.75003.x
- Farnsworth A (2011). Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective. Acta Cytol, 55, 307-12. https://doi.org/10.1159/000326956
- Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancerbase Lyon, France: International Agency for Research on Cancer.
- Ferlay JSH, Bray F, Forman D, Mathers C, Parkin Dm. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].Lyon, France: International Agency for Research on Cancer; 2010.
- Galarraga O, Colchero M A, Wamai R G ,Bertozzi S M (2009). HIV prevention cost-effectiveness: a systematic review. BMC Public Health, 9, 5. https://doi.org/10.1186/1471-2458-9-5
- Garber AM, Sox HC (2010). The role of costs in comparative effectiveness research. Health Affairs, 29, 1805-11. https://doi.org/10.1377/hlthaff.2010.0647
- Goldie S J, Gaffikin L, Goldhaber-Fiebert J D, et al (2005). Costeffectiveness of cervical-cancer screening in five developing countries. New Engl J Med, 353, 2158-68. https://doi.org/10.1056/NEJMsa044278
- Goldie SJ, Kim JJ, Kobus K, et al (2007). Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine, 25, 6257-70. https://doi.org/10.1016/j.vaccine.2007.05.058
- Goldie SJ, Kim JJ ,Wright T C (2004). Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstetrics Gynecol, 103, 619-31. https://doi.org/10.1097/01.AOG.0000120143.50098.c7
- Goldie SJ, Kuhn L, Denny L, et al (2001). Policy analysis of cervical cancer screening strategies in low-resource settings. JAMA, 285, 3107-15. https://doi.org/10.1001/jama.285.24.3107
- Hank E, Hoque ME, Zungu L (2013). Cervical precancerous lesions and cancer among patients in the gynaecology outpatient department at a tertiary hospital in South Africa. Asian Pac J Cancer Prev, 14, 4903-06. https://doi.org/10.7314/APJCP.2013.14.8.4903
- Hernandez R, Rabindranath K, Fraser C, et al (2008). Screening for open angle glaucoma: systematic review of costeffectiveness studies. Journal of glaucoma, 17, 159-68. https://doi.org/10.1097/IJG.0b013e31814b9693
- Higgins JP T, Green S ,Collaboration C (2008). Cochrane handbook for systematic reviews of interventions, Wiley Online Library.
- Hyewon H, Levine M (2012). Determing the Threshold of Acceptability of an ICER when Natural Health Units are used. J Popul Ther Clin Pharmacol, 19, 234.
- Jackson CH, Sharples LD, Thompson SG, et al (2003). Multistate Markov models for disease progression with classification error. The Statistician, 52, 193-209.
- Jhala D, Eltoum I (2007). Barriers to adoption of recent technology in cervical screening. CytoJournal, 4, 16. https://doi.org/10.1186/1742-6413-4-16
- Kim JJ, Wright TC ,Goldie S J (2005). Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, the netherlands, France, and Italy. J Nat Cancer Inst, 97, 888-95. https://doi.org/10.1093/jnci/dji162
- Kobayashi D, Takahashi O, Hikosaka C, Okubo T, Fukui T. (2013). Optimal cervical cytology mass screening interval for cervical cancer. Arch Gynecol Obstet, 287, 549-54. https://doi.org/10.1007/s00404-012-2588-8
- Kulasingam S, Rajan R, Yvan St Pierre C, et al (2009). Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med, 7, 69. https://doi.org/10.1186/1741-7015-7-69
- Levin C E, Sellors J, Shi JF, et al (2010). Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China. Int J Cancer, 127, 1404-11. https://doi.org/10.1002/ijc.25150
- Muhlberger N, Sroczynski G, Esteban E, et al (2008). Costeffectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German federal ministry of health. Int J Technol Assess Health Care, 24, 184-92.
- Malloy C, Sherris J, Herdman C (2000). HPV DNA Testing: Technical and Programmatic.
- Mandelblatt JS, Lawrence WF, Gaffikin L, et al (2002a). Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Nat Cancer Inst, 94, 1469-83. https://doi.org/10.1093/jnci/94.19.1469
- Mandelblatt JS, Lawrence WF, Womack SM, et al (2002b). Benefits and costs of using HPV testing to screen for cervical cancer. JAMA, 287, 2372-81. https://doi.org/10.1001/jama.287.18.2372
- Maxwell GL, Carlson JW, Ochoa M, et al (2002). Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstetrics Gynecol, 100, 740-48. https://doi.org/10.1016/S0029-7844(02)02195-6
- Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 1000097. https://doi.org/10.1371/journal.pmed.1000097
- Moore K, Cofer A, Elliot L, et al (2007). Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol, 197, 141.
- Nahar K, Nessa A, Shamim S, et al (2011). Role of VIA in cervical cancer screening in low-resource countries. Mymensingh Medical Journal, 20, 528-35.
- Naucler P, Ryd W, T Rnberg S, et al (2007). Human papillomavirus and Papanicolaou tests to screen for cervical cancer. New England Journal of Medicine, 357, 1589-97. https://doi.org/10.1056/NEJMoa073204
- Nessa A, Nahar KN, Begum SA, et al (2013). Comparison between visual inspection of cervix and cytology based screening procedures in Bangladesh. Asian Pac J Cancer Prev, 14, 7607-11. https://doi.org/10.7314/APJCP.2013.14.12.7607
- Nienhaus A, Schablon A, Costa JT, Diel R (2011). Systematic review of cost and cost-effectiveness of different TBscreening strategies. BMC Health Services Res, 11, 247. https://doi.org/10.1186/1472-6963-11-247
- Parashari A ,Singh V (2013). Reasons for variation in sensitivity and specificity of visual inspection with acetic acid (VIA) for the detection of pre-cancer and cancer lesions of uterine cervix. Asian Pac J Cancer Prev, 14, 7761-62. https://doi.org/10.7314/APJCP.2013.14.12.7761
- Reviews UOYCF, Dissemination, Akers J (2009). Systematic reviews: CRD' s guidance for undertaking reviews in health care, Centre for Reviews and Dissemination.
- Ries LaG (1999). SEER cancer statistics review, 1973-1996, us department of health and human services, public health service, national institutes of health, national cancer institute.
- Sachs JD (2002). Macroeconomics and health: investing in health for economic development. Rev Panam Salud Publica, 12, 143-44. https://doi.org/10.1590/S1020-49892002000800017
- Salit IE, Lytwyn A, Raboud J, et al (2010). The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS, 24, 1307-13.
- Sankaranarayanan R, Esmy PO, Thara S, et al (2012). Cervical cancer screening in the developing world. cervical cancer: con-temporary management. Jaypee Brothers Medical Publishers, 3-14.
- Schiffman M, Wentzensen N, Wacholder S, et al (2011). Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst, 103, 368-83. https://doi.org/10.1093/jnci/djq562
- Sharifah NA, Seeni A, Nurismah MI, et al (2009). Prevalence of human papillomavirus in abnormal cervical smears in Malaysian patients. Asian Pac J Cancer Prev, 10, 303-6.
- Sherlaw-Johnson C, Philips Z (2004). An evaluation of liquidbased cytology and human papillomavirus testing within the UK cervical cancer screening programme. Br J Cancer, 91, 84-91. https://doi.org/10.1038/sj.bjc.6601884
- Shiroiwa T, Sung YK, Fukuda T, et al (2010). International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Economics, 19, 422-37. https://doi.org/10.1002/hec.1481
- Simoens S (2010a). Health economic assessment: costeffectiveness thresholds and other decision criteria. Int J Environ Res Public Health, 7, 1835-40. https://doi.org/10.3390/ijerph7041835
- Simoens S (2010b). How to assess the value of medicines? Frontiers in pharmacology, 1.
- Sroczynski G, Schnell-Inderst P, Muhlberger N, et al (2011). Cost-effectiveness of primary HPV screening for cervical cancer in Germany-a decision analysis. Eur J Cancer, 47, 1633-46. https://doi.org/10.1016/j.ejca.2011.03.006
- Stat O Extracts: http://stats. oecd.org/wbos/Index.aspx.DatasetCode= LFS_SEXAGE_I_R (26/10/2008).
- Vijayaraghavan A, Efrusy M, Lindeque G, et al (2009). Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol, 112, 377-83. https://doi.org/10.1016/j.ygyno.2008.08.030
- Vijayaraghavan A, Efrusy MB, Goodman KA, et al (2010a). Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecologic Oncol, 119, 237-42. https://doi.org/10.1016/j.ygyno.2010.07.004
- Vijayaraghavan A, Efrusy MB, Mayrand MH, et al (2010b). Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. Canadian J Public Health, 101, 220-25.
- Wang J-L, Yang Y-Z, Dong W-W, et al (2013). Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pac J Cancer Prev, 14, 2979-82. https://doi.org/10.7314/APJCP.2013.14.5.2979
- Whitlock EP, Vesco KK, Eder M, et al (2011). Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the US Preventive Services Task Force. Ann Int Med, 155, 687-97. https://doi.org/10.7326/0003-4819-155-10-201111150-00376
- Williams A (2004). What could be nicer than NICE?, Office for Health Economics.
- Wright TC (2006). HPV DNA testing for cervical cancer screening. Int J Gynecol Obstetrics, 95, 239-46. https://doi.org/10.1016/S0020-7292(06)60039-8
Cited by
- Assessment of the Reliability of a Novel Self-sampling Device for Performing Cervical Sampling in Malaysia vol.16, pp.2, 2015, https://doi.org/10.7314/APJCP.2015.16.2.559
- Evaluation of Several Screening Approaches for Detection of Cervical Lesions in Rural Shandong, China vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1907
- Cost-effectiveness Analysis of Cervical Cancer Screening Strategies Based on the Papanicolaou Smear Test in Korea vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2317
- Priority Setting for Improvement of Cervical Cancer Prevention in Iran vol.5, pp.4, 2015, https://doi.org/10.15171/ijhpm.2015.201
- Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer vol.11, pp.6, 2016, https://doi.org/10.1371/journal.pone.0156705
- Comparative Assessment of a Self-sampling Device and Gynecologist Sampling for Cytology and HPV DNA Detection in a Rural and Low Resource Setting: Malaysian Experience vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8495
- Cost-Effectiveness Analysis of Breast Cancer Screening in Rural Iran vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.609
- The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis vol.93, pp.1, 2016, https://doi.org/10.1136/sextrans-2016-052609
- Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review vol.141, pp.3, 2017, https://doi.org/10.1002/ijc.30695
- Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening vol.73, pp.19805322, 2018, https://doi.org/10.6061/clinics/2018/e385